Female sexual dysfunction (FSD) effects women of all ages but is common among perimenopausal / postmenopausal women and may be related to a reduction in circulating estrogen. Oral estrogens increase sex hormone-binding globulin (SHBG) which lowers available free testosterone and thus may negatively impact sexual function.Transdermal estrogens are typically preferred because they lack a high first-pass effect and are not associated with risk of thromboembolic events. However, additional research – directly comparing oral and transdermal preparations – was needed. An ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS) did just that - examined the impact of oral and transdermal estrogens on sexual functioning.
Guest Authors: Stefanie C. Nigro, PharmD, BCACP and Christine Dimanculangan, Pharm.D.
Music by Good Talk